Biotech Daily Home
|
Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy. Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector. The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter. Base-rate subscriptions are $A1600 a year (including GST in Australia). Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.
|
|
Clarity $92m IPO For Cancer Radio-Pharmaceuticals Dr Boreham's Crucible: IDT Australia Zucero: FDA Cancer Trial Approval Delays $30m IPO Federal Budget 2021: 'Patent Box', R&D, ANSTO; Comment & Response Victoria: 'Funding Returns 366% GSP, 454% Income In 10 Years' A Year In The Grass - Medical Marijuana Review Biotech Daily 1st Medical Marijuana Survey CSIRO, Doherty Distance From 'Tier 1' Sars-Cov-2 Claims
August BDI-40 Up 12% To Record $23b Wednesday September 1, 2021 The BDI-40 was up 11.7 percent in August to a record $23,103 million, and up 41.3 percent for the year to August 31, 2021, while the benchmark ASX200 was up 1.9 percent to 7,535 points, and up 24.3 percent for the 12 months to August 31.
The collective three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) were up 7.2 percent in August to a record $215,852 million and up 21.5 percent for the year.
Cochlear fell a further 5.8 percent to $15,339 million, but that was easily offset by Resmed putting on 11.4 percent to $58,540 million and CSL – also known as The Magic Pudding – was up 7.2 percent to $141,973 million.
While Imugene’s $736 million August increase was the single largest contributor to the index, despite still being in early-stage trials with no revenue, Dimerix had a higher percentage leap (see below).
Mesoblast’s $162 million tumble in August to a market capitalization of $1,080 million – 65.2 percent below the same time last year – was easily offset by Pro Medicus up $510 million, Telix up $408 million, Nanosonics up $401 million and Clinuvel up $399 million.
Twenty-three of the BDI-40 companies were up, 15 by more than 10 percent and 10 by more than 25 percent in August. Fourteen companies fell, with seven down by more than 10 percent.
Dimerix was the best (from a low base) up $39 million or 81.25 percent to $87 million, followed by Imugene up 49.9 percent to $2,212 million, Neuren (35.9%), Ellex (32.6%), Pharmaxis (32.6%), Impedimed (31.7%), Clinuvel (27.2%), Telix (27.1%), LBT (26.7%), Nanosonics (25.1%), Genetic Signatures (18.4%), Cynata (11.9%), Kazia (11.6%), Universal Biosensors (10.7%), Immutep (10.5%) and Optiscan (10.3%).
Osprey led the falls, down $13 million or 31.7 percent to $28 million, followed by Resonance (30.3%), Patrys (19.8%), Orthocell (13.7%), Mesoblast (13.0%), Starpharma (10.8%) and Paradigm (10.7%).
Outside the BDI-40, Rhinomed put on a further 77.4 percent to $94 million on the back of its Rhinoswab deal with the New South Wales Government.
Cannabis Corner was up 10.3 percent to $1,724 million, with Incannex up $181 million or 66.3 percent to $454 million, and we checked it twice to make sure it wasn’t a hallucination.
On the Nasdaq, Queensland’s Protagonist eased 1.4 percent to $3,152 billion, Redhill with Australian assets climbed 57.3 percent to $645 million and Eyepoint (Psivida) improved 33.5 percent to $430 million.
The Nasdaq Biotechnology Index was up 4.1 percent in August to 5,348 points – up 25.5 percent for the year to August 31, 2021.
BDI-40 v S&P ASX200 Jun 30, 2006 to Aug 31, 2021
 5-Year Big Caps (Cochlear, CSL, Resmed) to Aug 31, 2021
 BDI-40 ($m) v S&P ASX200 – Jan 31, 2020 - Aug 31, 2021
(current, raw data) 
|
Click here for Biotech Daily's archive
Biotech Daily Top 40 With Market Capitalization At Aug 31, 2021
* Biotech Daily editor, David Langsam, owns shares in Acrux, Actinogen, Alcidion, Alterity, Amplia, BTC Health, Clarity, Cochlear
Control Bionics, Cynata, Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies.
These holdings are liable to change:
https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/.